Tevogen Bio Holdings Inc TVGN

$6.72 +0.78 (13.13%)

Valuation

Market cap
23,408,000
Revenue TTM
$0
Net income TTM
$-26,280,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
-0.65

Trading

Volume
24,207
Avg volume
26,388
Day's range
$6.12 – $7.42
Shares out
4,188,000
Stochastic %K
93%
Beta
0.20
Analysts
Strong Buy
Price target
$100.00

Price

Company profile

Tevogen Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in Phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune s...

Show more

Tevogen Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in Phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune suppression, and other B cell immune suppressed acute SARS-CoV-2 patients with a B cell cancer indication, as well as Long COVID prevention and treatment. It is also developing TVGN 920, a preclinical trial drug for treating cervical cancer; TVGN 960, a preclinical trial drug for treating oropharyngeal cancer; TVGN 601, a preclinical trial drug for treating multiple sclerosis; TVGN 930, a preclinical trial drug for treating Epstein-Barr virus associated lymphomas; and TVGN 116, a product candidate targeted at hepatitis B. It also offers artificial intelligence platform for drug development. Tevogen Inc. was formerly known as Tevogen Bio Holdings Inc. and changed its name to Tevogen Inc. in July 2026. The company was incorporated in 2020 and is headquartered in Warren, New Jersey.

Industry
Biotechnology
Sector
Healthcare
Phone
877 838 6436
Website
https://tevogen.com
Address
15 Independence Boulevard, Suite #210, Warren, United States

Latest news

Stocktwits

NGCS Sep 18, 12:04 PM
$TVGN Valuation Model based on Revenue Mix (MSO/CRO + Tevogen.AI Licences) 🧬🤖 Today there are only 6,4 million shares (float 3,5M - 4,2M shares). But even Assuming worst case fully diluted ~21M OS (including CEO 8M sh ONLY if $1B revenue milestones from last SEC filing on 16th sept): 🔹 Base Case ($250M Rev): $180M MSO + $70M AI = ~$65 - $70 / sh 🔹 Bull Case ($600M Rev): $400M MSO + $200M AI = ~$170 - $180 / sh 🔹 TechBio Mega Case ($1B Rev): $500M MSO + $500M AI = ~$360 - $380 / sh AI SaaS multiples (10x-15x) completely dwarf traditional CRO valuation. High margins = massive repricing. 📈 NFA - Do your own DD
0 replies
NGCS Sep 11, 7:09 AM
$TVGN https://www.investing.com/news/sec-filings/tevogen-regains-nasdaq-compliance-with-minimum-market-value-requirement-93CH-4896349
0 replies
NGCS Sep 11, 6:59 AM
$TVGN New SEC 8-K confirms $TVGN received formal written notice from NASDAQ: Minimum Market Value Compliance HAS BEEN MET and the matter is officially CLOSED. The regulatory overhang is gone. Now all eyes turn to the final catalyst: The MSO/CRO Definitive Agreement (PR/8-K) • Float: ~3.5M–4.2M (Extremely tight) • Short Interest: 68.5k shares with a ~13.4 Days to Cover! • Order Book: Completely empty on the Ask—a single spark clears the board. The stage is set for the M&A launch. IMO Short squeeze could happen in any moment. #TVGN #LowFloat #ShortSqueeze #Biotech #SEC #NASDAQ
0 replies
Chamelneon Sep 10, 10:47 AM
$TVGN Folks check out Avacta, AVCT in UK, much better chance of making some cash on that one then this! DYOR 😘
0 replies
mat70 Sep 2, 2:50 PM
$TVGN 2/2 The primary milestones that need to be met, ideally before EOY, would be closure of their LOI acquisition targets without significant shareholder dilution. That would provide immediate revenue to fund a) ongoing operations, and b) at least part or all of the next phase for TVGN-489. Second, they need to secure and productionize their manufacturing facility. If these milestones are hit, then in my opinion, it warrants a significant re-rating of the company's risk profile. This is a good test of management's ability to execute. If not, then further skepticism is warranted and the investment thesis begins to buckle. We shall see how things play out.
1 replies
mat70 Sep 2, 2:49 PM
$TVGN @robsmi63 1/2 Skepticism is warranted; scam is hyperbole. Yes, the communications are muddled particularly with the press release strategy, but the fundamentals remain intact for a reasonable investment thesis. The risk is high, as with any clinical stage biotech. FDA approvals take time. They don't happen overnight and there are other pieces to the puzzle that need to fall into place first. They already received Phase 1 IND clearance with TVGN-489, and by any measure, the trial was highly successful. Granted future trials will be more rigorous but that does lend to the credence of their tech and leading candidate. The executive team has decades of expertise and credibility in the field. There is no evidence they are charlatans. 1/2
3 replies
Nikniko55 Aug 31, 8:34 PM
$TVGN news?
1 replies
NGCS Aug 28, 4:56 PM
$TVGN Seen CV of management, I think this is a serious team and project; of course everything could work faster and better, but sincerely they have successfull experiences in Wall Street and big with some blockbusters (you can check in on internet). I didnot talk about Patel Family, but they made billions usd in Medical and Pharmas. So now it is time for this company IMO. NFA. Best regards
0 replies